JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B-cell Malignancies. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B-cell Malignancies.

NCT Number	NCT07065279
Lead Sponsor	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Conditions	B-cell Malignancies
Enrollment	36 participants
Start Date	2025-07
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-07-15